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EDITORIAL
Cardiovascular disease in 
sub-Saharan Africa
Globally, non-communicable diseases (NCDs) are the leading cause of death, accounting for 
nearly three-quarters of all deaths, led by cardiovascular diseases (CVD) – with ischaemic heart 
disease (IHD) and stroke being the leading cause of global cardiovascular (CV) mortality and a 
major cause of CV morbidity and disability.(1) CVD is an important cause of premature mortality 
and rising healthcare costs in all regions of the world; and is driven by rapidly evolving cardio-
metabolic, behavioural, psychological,  environmental, and social risk factors and determinants of 
health.(2) Consistent, comparable, and systematic analysis of trends and patterns in CVD are 
essential to guide public policy and provide benchmarks for decision-makers. 
Worldwide, prevalent cases of total CVD nearly doubled from 271 million in 1990 to 523 million 
in 2019, and the number of CVD deaths steadily increased from 12.1 million in 1990, reaching 
18.6 million in 2019. The global trends for disability-adjusted life years (DALYs) and years of life 
lost also increased significantly, and years lived with disability doubled from 17.7 million to 34.4 
million over that period. The total number of DALYs due to IHD has risen steadily since 1990, 
reaching 182 million DALYs, 9.14 million deaths in the year 2019, and 197 million prevalent cases 
of IHD in 2019. The total number of DALYs due to stroke has risen steadily since 1990, reaching 
143 million DALYs, 6.55 million deaths in the year 2019, and 101 million prevalent cases of 
stroke in 2019.(1) 
Sub-Saharan Africa (SSA) is unique epidemiologically. Unlike in every other region in the world, 
NCDs are the second most common cause of death in SSA, accounting for 2.6 million deaths 
(about 35% of all deaths in SSA).(3) In fact, in SSA, the leading cause of mortality is the composite 
of infections, maternal, neonatal, and nutritional diseases. Current predictions are that by the 
year 2030, NCDs will account for more than half of all deaths in SSA, and will be the leading 
cause of mortality, similar to other parts of the world.(4) While age-adjusted CVD mortality rates 
in SSA are much lower compared to high-income countries, the absolute number of CVD 
deaths has increased by more than 50% in the past 3 decades in SSA.(5) 
HEART FAILURE
Although there have been no population-based epidemiological studies of heart failure in Africa, 
there have been numerous hospital-based studies that give important insights into the incidence 
and prevalence of HF in SSA.(6-12) A recent meta-analysis of heart failure studies in SSA depicted 
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that hypertensive heart disease (39%) was the most common cause of heart failure in SSA, 
followed by cardiomyopathy (21%) and rheumatic heart disease – RHD (14%), with ischaemic 
heart disease (IHD) less frequent (7%).(13) In the THESUS–HF study, conducted in 9 African 
countries, heart failure was most commonly due to hypertension (45%), followed by RHD (14%), 
while IHD accounted for a lower percentage (~8%).(8) Similarly, hypertension was the most 
common cause of heart failure in the Heart of Soweto study.(7) A more contemporaneous 
study of heart failure in Africa including many patients from private hospitals reported IHD to 
account for 20% of heart failure hospitalisations, indicating evidence of epidemiological transition 
in urban centres.(9)
CVD and heart failure in Africa has traditionally been described as distinct to the profile seen in 
high-income countries, and as having the following characteristics: (i) occurring at a relatively 
young age and holding great public health relevance because of its high prevalence and impact 
on young economically active individuals, resulting in significant disability, premature death, and 
loss of economic productivity; (ii) largely due to non-ischaemic causes, with hypertensive heart 
disease, rheumatic heart disease (RHD) and cardiomyopathy accounting for majority of cases; (iii) 
heart failure, rather than IHD, is the dominant form of CVD in SSA; and common causes like 
RHD, idiopathic cardiomyopathy, peripartum cardiomyopathy, hypertensive heart disease and 
endomyocardial fibrosis present for the most part in the young; and (iv) infections remain a 
significant cause of CVD in Africans - pulmonale and pericarditis, largely due to tuberculosis, are 
important causes of heart failure in the region, while myocarditis, HIV, malaria and syphilis all 
contribute to the burden of CVD in the region.(6)
HYPERTENSION
In SSA, hypertension is a common medical condition of immense economic importance because 
of its high prevalence in urban areas, its frequent underdiagnosis, and the severity of its com-
plications.(14) More than a quarter of the global adult population has hypertension and this 
percentage is expected to increase in the coming years in all regions, particularly in SSA.(15) 
Prevalence of hypertension in SSA is approximately 30%.(16) There were approximately 80 million 
patients with hypertension in SSA in 2000, and projections based on current epidemiologic data 
suggest that this figure will rise to over 150 million by 2025.(17) The highest age-standardised rates 
of disability-adjusted life years (DALYs) due to hypertension are noted in SSA.(1) An over-
representation of DALYs due to hypertensive heart disease in African women is noted in 
Central and Eastern SSA.(1) Inequalities in access to both primary and secondary prevention are 
a potential cause of these regional and sex differences. Contemporary trends show regional 
variations with prevalence being associated with the rate of urbanisation and westernisation of 
lifestyle.(6) The global and regional prevalence of hypertensive heart disease and absolute rates of 
adverse outcomes are expected to continue to rise due to population growth, aging, increasing 
obesity, left ventricular hypertrophy and diabetes.(1,6) In black Africans, perhaps due to delayed 
and/or inadequate therapeutic management and to a likely genetic predisposition, organ-related 
complications are more common and occur earlier.(6) Stroke, heart failure and renal failure are 
frequent complications in young African patients, with significant social and economic implications. 
Intensified global and regional efforts to lower blood pressure and control other risk factors are 




Whereas Africa has 10% of the world’s population, as many as half of the 2.4 million children 
affected by RHD globally live on the continent.(6) RHD accounts for a major proportion of all 
CVD in children and young adults in African countries, and for 17% - 43% of all CVD in SSA, and 
over 300 000 deaths annually.(18) Global age-standardised mortality due to RHD decreased by 
48% from 1990 - 2015, but large differences were observed across regions. In 2015, the highest 
age-standardised mortality due to and prevalence of RHD was observed in Oceania, South Asia, 
and Central SSA. In 2015, there were 33.4 million cases of RHD and 10.5 million DALYs from 
RHD globally.(18)
CARDIOMYOPATHY
Cardiomyopathy in Africa may be endemic, as in dilated cardiomyopathy (DCM), peripartum 
cardiomyopathy (PPCM) and endomyocardial fibrosis, or to be non-endemic, as in hypertrophic 
cardiomyopathy (HCM), arrhythmogenic cardiomyopathy, and HIV-associated cardiomyopathy. 
Idiopathic DCM contends with hypertension and RHD as the leading causes of heart failure in 
Africa, accounting for 10% - 17% of all cardiac conditions encountered at autopsy and 20% - 
30% of cases of hospitalised heart failure in Africans.(6) In SSA, DCM occurs commonly in the 
third and fourth decades of life, with men affected twice as much as women. Two-thirds of 
African patients with DCM, especially those who are more than 55 years of age, have persistently 
low arterial blood pressure, ventricular arrhythmias and/or atrioventricular valve incompetence 
and die within 5 years of their first symptom.(19) 
ISCHAEMIC HEART DISEASE
Numerous historic reviews and reports have highlighted the rarity of IHD in SSA. In a study 
conducted in 1960, IHD was reported to be “extremely rare” in Africans,(20) and a separate 
report declared Africans to be “virtually free” from CAD.(21) Between 1992 and 1994, the Chris 
Hani Baragwanath Hospital reported a prevalence of 0.2% of IHD.(22) More recently, investiga-
tors of the Heart of Soweto demonstrated evidence of strong epidemiological transition 
occurring in urban Africans, with consequent “broadened complexity and spectrum of heart 
disease” in this group, with 10% of patients studied diagnosed with CAD.(7) Modifications in 
lifestyle, risk-prone behaviour, diet, cultural attitudes, limited physical activity and other con-
sequences of rapid urbanisation contribute to this epidemiological change. 
CONGENITAL HEART DISEASE
The estimated prevalence of congenital heart disease (CHD) of 8 per 1 000 live births is 
generally accepted as the most reliable globally, though much lower prevalence is observed in 
Africa, particularly among low-income populations, likely reflecting paucity of readily available 
estimates and the urgent need for robust data to support burden of disease calculations in 
Africa.(23) In addition, children with CHD in Africa have a poorer prognosis compared to those 
from high-income countries.(24) Untreated CHD contributed to the burden of paediatric heart 
failure in the region. 
In this issue of the Journal, we include publications on hypertension,(25) valvular heart disease 
interventions,(26) IHD diagnosis,(27,28) RHD surgery,(29) HIV associated myocarditis and cardio-
myopathy,(30) genomics of CHD,(31) and the role of cardiovascular magnetic resonance in the 
diagnosis and prognostication of HCM.(32) Obstacles hampering primary and secondary preven-
tion of CVDs in SSA include insufficient healthcare systems and infrastructure, scarcity of cardiac 
professionals, skewed budget allocation and disproportionate prioritisation away from NCDs, 
high cost of cardiac treatments and interventions coupled with rarity of health insurance systems. 
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